The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.
ASJC Scopus subject areas